Equities analysts expect Redhill Biopharma Ltd. (NASDAQ:RDHL) to post $1.27 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Redhill Biopharma’s earnings, with the lowest sales estimate coming in at $900,000.00 and the highest estimate coming in at $1.64 million. The company is expected to announce its next quarterly earnings results on Monday, November 13th.

According to Zacks, analysts expect that Redhill Biopharma will report full-year sales of $1.27 million for the current year, with estimates ranging from $2.78 million to $4.69 million. For the next fiscal year, analysts anticipate that the firm will post sales of $47.25 million per share, with estimates ranging from $11.01 million to $113.90 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) last announced its quarterly earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by $0.02. The company had revenue of $0.48 million during the quarter, compared to the consensus estimate of $0.34 million.

A number of brokerages have recently commented on RDHL. HC Wainwright set a $33.00 target price on shares of Redhill Biopharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Zacks Investment Research lowered shares of Redhill Biopharma from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Roth Capital set a $26.00 target price on shares of Redhill Biopharma and gave the stock a “buy” rating in a research report on Thursday, May 4th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Redhill Biopharma in a research report on Friday, June 16th.

ILLEGAL ACTIVITY WARNING: “Redhill Biopharma Ltd. (RDHL) Expected to Announce Quarterly Sales of $1.27 Million” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/18/redhill-biopharma-ltd-rdhl-expected-to-announce-quarterly-sales-of-1-27-million-updated.html.

Shares of Redhill Biopharma (RDHL) traded down 1.93% on Friday, reaching $8.64. The company had a trading volume of 36,282 shares. The firm’s market capitalization is $148.29 million. The stock’s 50 day moving average is $9.03 and its 200 day moving average is $9.63. Redhill Biopharma has a 52 week low of $8.16 and a 52 week high of $15.99.

Several institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp bought a new position in shares of Redhill Biopharma during the first quarter worth approximately $101,000. Family Management Corp bought a new position in shares of Redhill Biopharma during the first quarter worth approximately $163,000. Penserra Capital Management LLC raised its position in shares of Redhill Biopharma by 75.0% in the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock worth $171,000 after buying an additional 7,647 shares during the period. Oppenheimer & Co. Inc. raised its position in shares of Redhill Biopharma by 36.5% in the first quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock worth $221,000 after buying an additional 6,172 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of Redhill Biopharma during the fourth quarter worth approximately $266,000. 12.31% of the stock is currently owned by institutional investors and hedge funds.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Get a free copy of the Zacks research report on Redhill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Stock Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related stocks with our FREE daily email newsletter.